Form 4 holding
EVP of R&D
Allogene Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 541,946
- Estimated value
- $1,720,353
- Report date
- 07 Oct 2022
- Price
- $3.17
- Ownership
- Direct
Rafael Amado
Insider Reports History
- Reporting-owner location
- Cambridge, MA
- Latest reporting-owner signature
-
/s/ Bruce Blefeld, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Rafael Amado
Form 4 holding
President, Head of Global Oncology Research and Development
Zai Lab Ltd
- Security class
- American Depositary Shares
- Shares / value
- 57,022
- Estimated value
- $1,165,985
- Report date
- 06 Apr 2026
- Price
- $20.45
- Ownership
- Direct
Form 4 holding
President, Head of Global Oncology Research and Development
Zai Lab Ltd
- Security class
- Restricted Share Units
- Shares / value
- 5,391
- Estimated value
- $387,009
- Report date
- 02 Apr 2026
- Price
- $35.89
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
Form 4 holding
Director
Poseida Therapeutics, Inc.
- Security class
- Common Stock
- Shares / value
- 0
- Estimated value
- $0
- Report date
- 08 Jan 2025
- Price
- $9.60
- Ownership
- Direct
Form 4 holding
President, Head of Global Oncology Research and Development
Zai Lab Ltd
- Security class
- Stock Options (Right to Buy)
- Shares / value
- 103,950
- Estimated value
- Report date
- 04 Mar 2026
- Price
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
Form 4 holding
President, Head of Global Oncology Research and Development
Zai Lab Ltd
- Security class
- Performance-Based Share Units
- Shares / value
- 14,905
- Estimated value
- Report date
- 04 Mar 2026
- Price
- Ownership
- Direct
- Underlying class
- American Depositary Shares
- Underlying amount
Form 4 holding
Director
Poseida Therapeutics, Inc.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 0
- Estimated value
- Report date
- 08 Jan 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Rafael Amado
4
ZLAB
Zai Lab Ltd
- Report period
- 06 Apr 2026
- Transactions
- 1
- Transaction value
- -$56,007
- Accepted by SEC
- 08 Apr 2026, 19:33
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 04 Mar 2026
- Transactions
- 6
- Transaction value
- -$202,065
- Accepted by SEC
- 03 Apr 2026, 17:57
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 04 Mar 2026
- Transactions
- 5
- Transaction value
- -$55,083
- Accepted by SEC
- 16 Mar 2026, 16:07
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 03 Mar 2026
- Transactions
- 1
- Transaction value
- -$173,800
- Accepted by SEC
- 05 Mar 2026, 16:07
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 30 Dec 2025
- Transactions
- 3
- Transaction value
- -$188,039
- Accepted by SEC
- 02 Jan 2026, 16:15
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 08 Aug 2025
- Transactions
- 1
- Transaction value
- -$105,000
- Accepted by SEC
- 12 Aug 2025, 16:45
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 03 Apr 2025
- Transactions
- 3
- Transaction value
- -$100,284
- Accepted by SEC
- 07 Apr 2025, 16:48
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 01 Apr 2025
- Transactions
- 3
- Transaction value
- -$270,677
- Accepted by SEC
- 03 Apr 2025, 17:06
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 17 Mar 2025
- Transactions
- 1
- Transaction value
- -$115,230
- Accepted by SEC
- 19 Mar 2025, 16:41
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 12 Mar 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Mar 2025, 17:14
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
Poseida Therapeutics, Inc.
- Report period
- 08 Jan 2025
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 08 Jan 2025, 14:17
- Role
- Director
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 30 Dec 2024
- Transactions
- 3
- Transaction value
- -$199,289
- Accepted by SEC
- 02 Jan 2025, 16:13
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 12 Aug 2024
- Transactions
- 1
- Transaction value
- -$50,463
- Accepted by SEC
- 14 Aug 2024, 16:18
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
Poseida Therapeutics, Inc.
- Report period
- 17 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 18 Jun 2024, 16:12
- Role
- Director
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 03 Apr 2024
- Transactions
- 3
- Transaction value
- +$55,123
- Accepted by SEC
- 05 Apr 2024, 17:47
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 01 Apr 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Apr 2024, 21:43
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 15 Mar 2024
- Transactions
- 1
- Transaction value
- -$47,980
- Accepted by SEC
- 19 Mar 2024, 16:12
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 29 Dec 2023
- Transactions
- 5
- Transaction value
- -$509,169
- Accepted by SEC
- 03 Jan 2024, 19:26
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
Poseida Therapeutics, Inc.
- Report period
- 01 May 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 02 May 2023, 16:14
- Role
- Director
- Next action
- Open filing details
3
Poseida Therapeutics, Inc.
- Report period
- 13 Apr 2023
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 14 Apr 2023, 17:23
- Role
- Director
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 03 Apr 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 05 Apr 2023, 16:05
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
4
ZLAB
Zai Lab Ltd
- Report period
- 30 Dec 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2023, 15:10
- Role
- President, Head of Global Oncology Research and Development
- Next action
- Open filing details
3
ZLAB
Zai Lab Ltd
- Report period
- 30 Dec 2022
- Transactions
- 0
- Transaction value
- $0
- Accepted by SEC
- 03 Jan 2023, 15:05
- Role
- President, Head of Global Oncology Research and Development Exhibit List: Exhibit 24 - Power of Attorney
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 07 Oct 2022
- Transactions
- 2
- Transaction value
- -$100,099
- Accepted by SEC
- 11 Oct 2022, 16:35
- Role
- EVP of R&D
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 03 Oct 2022
- Transactions
- 1
- Transaction value
- -$99,201
- Accepted by SEC
- 05 Oct 2022, 16:02
- Role
- EVP of R&D
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 02 Aug 2022
- Transactions
- 1
- Transaction value
- -$23,940
- Accepted by SEC
- 02 Aug 2022, 17:40
- Role
- EVP of R&D and CMO
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 05 Jul 2022
- Transactions
- 1
- Transaction value
- -$22,880
- Accepted by SEC
- 06 Jul 2022, 16:16
- Role
- EVP of R&D and CMO
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 21 Jun 2022
- Transactions
- 1
- Transaction value
- -$22,360
- Accepted by SEC
- 22 Jun 2022, 16:47
- Role
- EVP of R&D and CMO
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 19 May 2022
- Transactions
- 1
- Transaction value
- -$85,092
- Accepted by SEC
- 19 May 2022, 17:40
- Role
- EVP of R&D and CMO
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 23 Mar 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 25 Mar 2022, 17:52
- Role
- EVP of R&D and CMO
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 15 Mar 2022
- Transactions
- 1
- Transaction value
- -$39,848
- Accepted by SEC
- 17 Mar 2022, 17:59
- Role
- EVP of R&D and CMO
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 01 Oct 2021
- Transactions
- 1
- Transaction value
- -$280,185
- Accepted by SEC
- 04 Oct 2021, 17:55
- Role
- EVP of R&D and CMO
- Next action
- Open filing details
4
ALLO
Allogene Therapeutics, Inc.
- Report period
- 18 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 20 May 2021, 17:22
- Role
- EVP of R&D and CMO
- Next action
- Open filing details